Instead of creating a more potent version of popular GLP-1 obesity drugs, Moonwalk is developing a therapy with a different biological mechanism. Their goal is to offer meaningful weight loss but with fewer side effects like muscle loss and GI issues, and with less frequent dosing (once every six months).
Moonwalk's discovery engine combines broad, large-scale analysis of public genetic data from millions of individuals with deep, proprietary epigenetic data generated from fat cell samples. This unique data-layering approach allows them to identify novel causal links to obesity that other researchers may have missed.
Moonwalk enhances a commercial large language model by training it on their vast internal datasets of genetic, epigenetic, and siRNA screening results. This transforms the general AI into a specialized expert that can prioritize drug targets and generate unique biological insights, creating a significant competitive advantage.